RNA Targeted Therapeutics Market to Flourish Owing to High Unmet Medical Needs
The RNA targeted therapeutics market involves the development of drugs that modulate gene expression through RNA interference or antisense mechanisms to treat various diseases. RNA plays a crucial role in regulating many cellular processes through gene expression, making it an appealing target for drug development. RNA targeted therapies offer advantages like high specificity, potency and duration of action. The growing understanding of RNA biology and its role in disease pathogenesis has led to an increased focus on RNA as a therapeutic target.
The Global RNA Targeted Therapeutics Market is estimated to be valued at US$ 1.34 Bn in 2024 and is expected to exhibit a CAGR of 35% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the RNA Targeted Therapeutics are Abivax,AC Immune,Arrakis Therapeutics,eFFECTOR Therapeutics,Eloxx Pharmaceuticals. These players are developing novel RNA targeted drugs that can selectively block disease-driving transcripts to treat various conditions.
Key players operating in the RNA targeted therapeutics market are developing innovative molecules targeting diseases with significant unmet medical needs. Some of the key players in this market include Abivax, AC Immune, Arrakis Therapeutics, eFFECTOR Therapeutics, Eloxx Pharmaceuticals.
The global expansion of the RNA targeted therapeutics market is supported by ongoing clinical trials evaluating safety and efficacy of novel RNA targeted drugs. The market is witnessing increased investments from pharmaceutical companies and venture capital firms which is amplifying research activities. Several collaborative partnerships between academic institutions and companies are also boosting development of RNA targeted therapies worldwide.
Market drivers
The key driver for the high growth of RNA targeted therapeutics market is the presence of large number of difficult to treat diseases lacking effective treatment options. Diseases like cystic fibrosis and Duchenne muscular dystrophy have limited treatment options and represent major areas of unmet need. RNA targeted therapies have potential to treat the underlying cause of such diseases, thereby driving their demand. Additionally, growing RNA research and advances in delivery technologies are further expanding potential applications of RNA targeted drugs.
PEST Analysis
Political: The governments are funding research activities related to RNA targeted therapeutics. Various regulations support the clinical trials and approvals of novel RNA drugs.
Economic: The rising healthcare expenditures and increasing personal disposable incomes are fueling the demand for advanced therapeutic alternatives like RNA targeted therapeutics.
Social: The growing awareness among patients regarding innovative treatment options is boosting the acceptance of RNA targeted drugs. The social media is promoting the benefits of precision medicines.
Technological: Next-generation sequencing technologies are enabling comprehensive profiling of RNA actions. Novel delivery systems like nanocarriers are improving the efficacy and tolerability of RNA drugs. Computational tools are accelerating drug design and development processes.
Around 30% of the total market value is concentrated in North America due to established healthcare infrastructure, high adoption of advanced therapies, and strong presence of leading manufacturers in the US and Canada. The European countries including Germany, France, and the UK collectively account for 25% share owing to sizeable research spending and supportive regulatory environment.
The Asia Pacific region is emerging as the fastest growing market for RNA targeted therapeutics. It is estimated to expand at a CAGR of around 40% during the forecast period. Factors such as rising healthcare expenditure, growing focus on R&D activities, and increasing outsourcing of clinical trials to countries like China and India are boosting the regional market growth. Japan remains a major contributor to the Asia Pacific market.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
